Tetsu Niwa

Prof. Tetsu Niwa

Diagnostic Radiology, Tokai University School of Medicine, Isehara, Kanagawa, Japan
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2016 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
NAN. Aida
N. Aida
TNTetsu Niwa
Tetsu Niwa
YFY. Fujii
Y. Fujii
KNK. Nozawa
K. Nozawa
MEM. Enokizono
M. Enokizono
TOT. Obata
T. Obata
BACKGROUND AND PURPOSE: T1-weighted pointwise encoding time reduction with radial acquisition (PETRA) sequences require limited gradient activity and allow quiet scanning. We aimed to assess the usefulness of PETRA in pediatric brain imaging. MATERIALS AND METHODS: We included consecutive pediatric patients who underwent both MPRAGE and PETRA. The contrast-to-noise and contrast ratios between WM and GM were compared in the cerebellar WM, internal capsule, and corpus callosum. The degree of myelination was rated by using 4-point scales at each of these locations plus the subcortical WM in the anterior frontal, anterior temporal, and posterior occipital lobes. Two radiologists made all assessments, and the intra- and interrater agreement was calculated by using intraclass correlation coefficients. Acoustic noise on MPRAGE and PETRA was measured. RESULTS: We included 56 patients 5 days to 14 years of age (mean age, 36.6 months) who underwent both MPRAGE and PETRA. The contrast-to-noise and contrast ratios for PETRA were significantly higher than those for MPRAGE (P < .05), excluding the signal ratio for cerebellar WM. Excellent intra- and interrater agreement were obtained for myelination at all locations except the cerebellar WM. The acoustic noise on PETRA (58.2 dB[A]) was much lower than that on MPRAGE (87.4 dB[A]). CONCLUSIONS: PETRA generally showed better objective imaging quality without a difference in subjective image-quality evaluation and produced much less acoustic noise compared with MPRAGE. We conclude that PETRA can substitute for MPRAGE in pediatric brain imaging.

1 May 2017 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
MEMikako Enokizono
Mikako Enokizono
NANoriko Aida
Noriko Aida
TNTetsu Niwa
Tetsu Niwa
HOHitoshi Osaka
Hitoshi Osaka
TNTakuya Naruto
Takuya Naruto
NMNaomichi Matsumoto
Naomichi Matsumoto

1 December 2021 in The Journal of Pediatrics
Verified
Journal Article
Closed access
JSJun Shibasaki
Jun Shibasaki
TNTetsu Niwa
Tetsu Niwa
APAurélie Piedvache
Aurélie Piedvache
MTMoyoko Tomiyasu
Moyoko Tomiyasu
NMNaho Morisaki
Naho Morisaki
NANoriko Aida
Noriko Aida

4 August 2016 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
PDF file
TNTetsu Niwa
Tetsu Niwa
KNKumiko Nozawa
Kumiko Nozawa
NANoriko Aida
Noriko Aida

16 December 2020 in Acta Radiologica
Verified
Journal Article
Open access
PDF file
XSXuyang Sun
Xuyang Sun
TNTetsu Niwa
Tetsu Niwa
SOSoji Ozawa
Soji Ozawa
JEJun Endo
Jun Endo
JHJun Hashimoto
Jun Hashimoto
Using conventional computed tomography (CT), the accurate diagnosis of lymph node (LN) metastasis of esophageal cancer is difficult. To examine dual-energy CT parameters to predict LN metastasis preoperatively in patients with esophageal cancer. Twenty-six consecutive patients who underwent dual-energy CT before an esophageal cancer surgery (19 patients with LN metastases) were analyzed. The included LNs had a short-axis diameter of ≥4 mm and were confirmed to be resected on postoperative CT. Their short-axis diameter, CT value, iodine concentration (IC), and fat fraction were measured on early- and late-phase contrast-enhanced dual-energy CT images and compared between pathologically confirmed metastatic and non-metastatic LNs. In total, 51 LNs (34 metastatic and 17 non-metastatic) were included. In the early phase, IC and fat fraction were significantly lower in the metastatic than in the non-metastatic LNs (IC = 1.6 mg/mL vs. 2.2 mg/mL; fat fraction = 20.3% vs. 32.5%; both P < 0.05). Furthermore, in the late phase, IC and fat fraction were significantly lower in the metastatic than in the non-metastatic LNs (IC = 2.0 mg/mL vs. 3.0 mg/mL; fat fraction = 20.4% vs. 33.0%; both P < 0.05). Fat fraction exhibited accuracies of 82.4% and 78.4% on early- and late-phase images, respectively. Conversely, short-axis diameter and CT value on both early- and late-phase images were not significantly different between the metastatic and non-metastatic LNs (P > 0.05). Using dual-energy CT images, IC and fat fraction are useful for diagnosing LN metastasis in patients with esophageal cancer.

11 September 2014 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
KOKazumasa Odagiri
Kazumasa Odagiri
MOMotoko Omura
Motoko Omura
MHMasaharu Hata
Masaharu Hata
NANoriko Aida
Noriko Aida
TNTetsu Niwa
Tetsu Niwa
TITomio Inoue
Tomio Inoue
Standard treatment strategies for embryonal central nervous system (CNS) tumors have not yet been established. We treated these tumors using an original chemoradiation therapy protocol; the clinical outcomes and toxicities were retrospectively evaluated. Twenty-four patients were enrolled including sixteen with medulloblastoma, four with supratentorial primitive neuroectodermal tumor (sPNET), three with atypical teratoid/rhabdoid tumor, and one with pineoblastoma. Immediately after diagnosis, all patients underwent surgery initially. They were then categorized as high- or average-risk groups independent of tumor type/pathogenesis. The average-risk group included patients who were aged ≥3 years at diagnosis, had non-metastatic disease at diagnosis (M0), and had undergone gross total resection. Other patients were categorized as the high-risk group; this group received more intensive treatment than the average-risk group, including high-dose chemotherapy with autologous stem-cell transplantation. All patients received craniospinal irradiation (CSI). The CSI dose was 23.4 Gy for M0 patients aged ≥5 years, 18 Gy for M0 patients aged <5 years, and 30–36 Gy for all patients with M + disease. The total dose to the primary tumor bed was 54 Gy. The median follow-up time was 73.5 (range, 19–118) months. The 5-year progression-free survival (PFS) and overall survival (OS) rates were 71.1 and 88.9%, respectively in the average-risk group (n = 9) and 66.7 and 71.1%, respectively in the high-risk group (n = 15). The PFS and OS rates were not significantly different between the average- and high-risk groups. In patients with medulloblastoma only, these rates were also not significantly different between the average- and high-risk groups. Three of four patients with sPNET were disease free. The height standard deviation score (SDS) was significantly decreased at the last assessment relative to that at diagnosis (P < 0.0001). The latest median height SDS was -1.6 (range, 0.9 to -4.8), and the latest median full-scale intelligence quotient (FSIQ) score was 86 (range, 59–128). The CSI doses and age at the start of radiation therapy did not influence clinical outcomes, height SDSs, and FSIQ scores. Our original protocol for patients with embryonal CNS tumors was feasible and yielded favorable clinical outcomes.